Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push

Merck & Co. and Moderna’s personalized mRNA cancer vaccine has successfully lengthened recurrence-free survival when paired with Keytruda for patients with high-risk skin cancer. The phase 3 win sets the partners up to potentially seek accelerated approval.